{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:59:05Z","timestamp":1782255545971,"version":"3.54.5"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"12","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Earlier in vitro work demonstrated that PARP inhibition induces cell death in PTEN-null endometrial cancer cell lines, but the in vivo therapeutic efficacy of these agents against endometrial cancer remains unknown. Here, we test the efficacy of AZD2281 (olaparib), an oral PARP inhibitor, in the therapy of PTEN-null endometrial tumors in a preclinical endometrial cancer mouse model. Primary endometrial tumors were generated by epithelial loss of PTEN using an in vivo model. This model recapitulates epithelial-specific loss of PTEN seen in human tumors, and histologically resembles endometrioid carcinomas, the predominant subtype of human endometrial cancers. Olaparib was administered orally to tumor-bearing mice in two hormonal extremes: high or low estrogen. Olaparib treatment achieved a significant reduction in tumor size in a low estrogenic milieu. In striking contrast, no response to olaparib was seen in tumors exposed to high levels of estrogen. Two key observations were made when estrogen levels were dropped: (i) the serum concentration of olaparib was significantly increased, resulting in sustained PARP inhibition at the tumor bed; and (ii) the homologous recombination pathway was compromised, as evidenced by decreased Rad51 protein expression and function. These two mechanisms may account for the sensitization of PTEN-null tumors to olaparib with estrogen deprivation. Results of this preclinical trial suggest that orally administered PARP inhibitors in a low estrogenic hormonal milieu can effectively target PTEN-null endometrial tumors. Extension of this work to clinical trials could personalize the therapy of women afflicted with advanced endometrial cancer using well-tolerated orally administered therapeutic agents. Mol Cancer Ther; 12(12); 2917\u201328. \u00a92013 AACR.<\/jats:p>","DOI":"10.1158\/1535-7163.mct-13-0572","type":"journal-article","created":{"date-parts":[[2013,11,12]],"date-time":"2013-11-12T23:07:50Z","timestamp":1384297670000},"page":"2917-2928","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition\n                    <i>In Vivo<\/i>"],"prefix":"10.1158","volume":"12","author":[{"given":"Deanna M.","family":"Janzen","sequence":"first","affiliation":[{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.","family":"Paik","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Rosales","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Yep","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghui","family":"Cheng","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen N.","family":"Witte","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"},{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"},{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"},{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin","family":"Kayadibi","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Jung","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kym","family":"Faull","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaz","family":"Memarzadeh","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"},{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"},{"name":"Authors' Affiliations: Departments of 1Obstetrics and Gynecology, 2Molecular and Medical Pharmacology, 3Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine; Departments of 4Microbiology, Immunology and Molecular Genetics, 5Chemistry and Biochemistry, University of California Los Angeles; 6The VA Greater Los Angeles Health Care System, Los Angeles; 7Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles; and 8The Howard Hughes Medical Institute, University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2013,12,5]]},"reference":[{"key":"2022060800211645900_bib1","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1634\/theoncologist.2010-0091","article-title":"Treatment for advanced and recurrent endometrial carcinoma: combined modalities","volume":"15","author":"Rauh-Hain","year":"2010","journal-title":"Oncologist"},{"key":"2022060800211645900_bib2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdl417","article-title":"Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration","volume":"18","author":"Humber","year":"2007","journal-title":"Ann Oncol"},{"key":"2022060800211645900_bib3","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/S1470-2045(12)70213-9","article-title":"Markers for individualised therapy in endometrial carcinoma","volume":"13","author":"Salvesen","year":"2012","journal-title":"Lancet Oncol"},{"key":"2022060800211645900_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.pathol.4.110807.092311","article-title":"PTEN and the PI3-kinase pathway in cancer","volume":"4","author":"Chalhoub","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"2022060800211645900_bib5","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1158\/1078-0432.CCR-10-0540","article-title":"A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas","volume":"17","author":"Rudd","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022060800211645900_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"2022060800211645900_bib7","doi-asserted-by":"crossref","first-page":"53ra75","DOI":"10.1126\/scitranslmed.3001538","article-title":"PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors","volume":"2","author":"Dedes","year":"2010","journal-title":"Sci Transl Med"},{"key":"2022060800211645900_bib8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/annonc\/mdq322","article-title":"A review of PARP inhibitors: from bench to bedside","volume":"22","author":"Underhill","year":"2011","journal-title":"Ann Oncol"},{"key":"2022060800211645900_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"2022060800211645900_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"2022060800211645900_bib11","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/483519a","article-title":"Drug candidates derailed in case of mistaken identity","volume":"483","author":"Ledford","year":"2012","journal-title":"Nature"},{"key":"2022060800211645900_bib12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"2022060800211645900_bib13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"2022060800211645900_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cell.2006.11.042","article-title":"Essential role for nuclear PTEN in maintaining chromosomal integrity","volume":"128","author":"Shen","year":"2007","journal-title":"Cell"},{"key":"2022060800211645900_bib15","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1093\/nar\/gks270","article-title":"Homologous recombination and its regulation","volume":"40","author":"Krejci","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"2022060800211645900_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","volume":"1","author":"Mendes-Pereira","year":"2009","journal-title":"EMBO Mol Med"},{"key":"2022060800211645900_bib17","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1158\/1078-0432.CCR-11-2189","article-title":"PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy","volume":"18","author":"Fraser","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022060800211645900_bib18","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-09-2758","article-title":"Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors","volume":"16","author":"Mukhopadhyay","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022060800211645900_bib19","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrclinonc.2010.172","article-title":"Synthetic lethal approaches to breast cancer therapy","volume":"7","author":"Rehman","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2022060800211645900_bib20","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2165\/11635510-000000000-00000","article-title":"PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer","volume":"72","author":"Basu","year":"2012","journal-title":"Drugs"},{"key":"2022060800211645900_bib21","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/nar\/gkp1063","article-title":"Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability","volume":"38","author":"Schild","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"2022060800211645900_bib22","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1012548107","article-title":"Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium","author":"Memarzadeh","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060800211645900_bib23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/jnci\/92.11.924","article-title":"Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers","volume":"92","author":"Mutter","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2022060800211645900_bib24","first-page":"3605","article-title":"High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in Pten+\/- mice","volume":"60","author":"Stambolic","year":"2000","journal-title":"Cancer Res"},{"key":"2022060800211645900_bib25","first-page":"139087","article-title":"The synergistic effect of conditional Pten loss and oncogenic K-ras mutation on endometrial cancer development occurs via decreased progesterone receptor action","author":"Kim","year":"2010","journal-title":"J Oncol"},{"key":"2022060800211645900_bib26","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.yexcr.2011.03.006","article-title":"Adenovirus mediated homozygous endometrial epithelial Pten deletion results in aggressive endometrial carcinoma","volume":"317","author":"Joshi","year":"2011","journal-title":"Exp Cell Res"},{"key":"2022060800211645900_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2011.10.009","article-title":"The epidemiology of endometrial and ovarian cancer","volume":"26","author":"Cramer","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"2022060800211645900_bib28","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/stem.1337","article-title":"Estrogen and progesterone together expand murine endometrial epithelial progenitor cells","volume":"31","author":"Janzen","year":"2013","journal-title":"Stem Cells"},{"key":"2022060800211645900_bib29","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/0008-5472.CAN-06-4202","article-title":"Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development","volume":"67","author":"Jiao","year":"2007","journal-title":"Cancer Res"},{"key":"2022060800211645900_bib30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1210\/jcem-60-1-174","article-title":"Effects of aging and obesity on aromatase activity of human adipose cells","volume":"60","author":"Cleland","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"2022060800211645900_bib31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrc3397","article-title":"Future directions in cancer prevention","volume":"12","author":"Umar","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2022060800211645900_bib32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/13697137.2011.642427","article-title":"Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients","volume":"15","author":"Kunovac Kallak","year":"2012","journal-title":"Climacteric"},{"key":"2022060800211645900_bib33","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1158\/1078-0432.CCR-08-0214","article-title":"Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts","volume":"14","author":"Kinders","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022060800211645900_bib34","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1349-7006.2011.02179.x","article-title":"A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors","volume":"103","author":"Yamamoto","year":"2012","journal-title":"Cancer Sci"},{"key":"2022060800211645900_bib35","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10637-011-9682-9","article-title":"Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study","volume":"30","author":"Samol","year":"2012","journal-title":"Invest New Drugs"},{"key":"2022060800211645900_bib36","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/bjc.2011.555","article-title":"Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours","volume":"106","author":"Dean","year":"2012","journal-title":"Br J Cancer"},{"key":"2022060800211645900_bib37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1124\/dmd.112.046276","article-title":"Isoform-specific regulation of cytochromes p450 expression by estradiol and progesterone","volume":"41","author":"Choi","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"2022060800211645900_bib38","first-page":"4561","article-title":"Hormone-dependent regulation of BRCA1 in human breast cancer cells","volume":"55","author":"Gudas","year":"1995","journal-title":"Cancer Res"},{"key":"2022060800211645900_bib39","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/carcin\/bgi339","article-title":"Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells","volume":"27","author":"Buterin","year":"2006","journal-title":"Carcinogenesis"},{"key":"2022060800211645900_bib40","first-page":"1373","article-title":"Transcriptional activation of E2F1 gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1\/estrogen receptor interactions","volume":"13","author":"Wang","year":"1999","journal-title":"Mol Endocrinol"},{"key":"2022060800211645900_bib41","first-page":"301","article-title":"The ups and downs of DNA repair biomarkers for PARP inhibitor therapies","volume":"1","author":"Wang","year":"2011","journal-title":"Am J Can Res"},{"key":"2022060800211645900_bib42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"2022060800211645900_bib43","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/03602539709037591","article-title":"Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors","volume":"29","author":"Rendic","year":"1997","journal-title":"Drug Metab Rev"},{"key":"2022060800211645900_bib44","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10637-012-9922-7","article-title":"Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery","volume":"31","author":"Bundred","year":"2013","journal-title":"Invest New Drugs"},{"key":"2022060800211645900_bib45","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00109-006-0146-1","article-title":"Molecular analysis of human endometrium: short-term tibolone signaling differs significantly from estrogen and estrogen + progestagen signaling","volume":"85","author":"Hanifi-Moghaddam","year":"2007","journal-title":"J Mol Med"},{"key":"2022060800211645900_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2013.01.006","article-title":"Therapeutic applications of PARP inhibitors: anticancer therapy and beyond","author":"Curtin","year":"2013","journal-title":"Mol Aspects Med"},{"key":"2022060800211645900_bib47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0960-0760(03)00352-2","article-title":"An integrated view of aromatase and its inhibition","volume":"86","author":"Miller","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2022060800211645900_bib48","first-page":"650","article-title":"The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers\u2013a study of the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Ma","year":"2004","journal-title":"Int J Gynecol Cancer"},{"key":"2022060800211645900_bib49","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1006\/gyno.2000.5865","article-title":"A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"78","author":"Rose","year":"2000","journal-title":"Gynecol Oncol"},{"key":"2022060800211645900_bib50","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrclinonc.2011.42","article-title":"Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer","volume":"8","author":"Forster","year":"2011","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Molecular Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/12\/12\/2917\/2325492\/2917.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/12\/12\/2917\/2325492\/2917.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T20:40:02Z","timestamp":1654634402000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/mct\/article\/12\/12\/2917\/91554\/Low-Levels-of-Circulating-Estrogen-Sensitize-PTEN"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,1]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,12,5]]},"published-print":{"date-parts":[[2013,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1535-7163.mct-13-0572","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1535-7163.c.6535642","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22497520","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22497514.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22497532","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22497520.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22497517.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.c.6535642.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22497526.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22497532.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22497517","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22497529.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22497529","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22497514","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22497526","asserted-by":"object"}]},"ISSN":["1535-7163","1538-8514"],"issn-type":[{"value":"1535-7163","type":"print"},{"value":"1538-8514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,1]]}}}